Bullish
BioMarin has reported encouraging 3-year extension data for vosoritide (Voxzogo) in children with hypochondroplasia, showing sustained growth improvem...
Bullish
BioMarin Pharmaceutical Inc. presented positive three-year data for VOXZOGO in children with hypochondroplasia, showing improved height standard devia...
BioMarin Pharmaceutical has released positive 3-year data for Voxzogo and early results for BMN 333, both treatments for growth disorders. The announc...
Neutral
Catalyst Funds Management Pty Ltd purchased a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the fourth quarter, accordin...
Neutral
Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the ...